ISSN 0048-5713
13 papers in the library · 164 citations · publishing 1994-2024
Psychiatric Annals March 1, 1994 David M. Mcdowell, Herbert D. Kleber 75 citations
MDMA (3,4-methylenedioxymethamphetamine) has been classified as a Schedule I drug in the United States since July 1985, making it effectively illegal. This scheduling places it in the most restrictive category of controlled substances, defined as having no currently accepted medical use and a high potential for abuse.
Psychiatric Annals December 1, 2022 Justin Morales, Erik Quan, Arslaan Arshed et al. 27 citations
Psychedelic-assisted therapy research is growing, but racial and ethnic minority groups remain underrepresented in clinical trials. This article traces the history of psychedelics and their recent resurgence, explains how psychedelic medicine has been racialized, and documents current inequities in the field. It proposes an antiracism framework to decolonize psychedelic research by dismantling White power structures and returning authority to Indigenous cultures. The authors argue that the psychedelic movement has a rare opportunity to improve inclusion and show how to achieve it.
Psychiatric Annals March 1, 1994 George K. Aghajanian 27 citations
By the early 1960s, the serotonin (5-HT) hypothesis had become the dominant explanation for how LSD produces its effects, firmly established in the field of neuroscience and psychology.
Psychiatric Annals March 1, 1994 Mark S. Gold 11 citations
Surveys of high school students indicate that use of LSD and other hallucinogens appears to be increasing.
Psychiatric Annals September 1, 2022 Brian S. Barnett, Jeremy Weleff 6 citations
Psychedelics such as LSD, MDMA, and psilocybin may hold treatment potential for alcohol, opioid, tobacco, and other substance use disorders, based on growing evidence from observational studies and clinical trials. The mechanisms are not fully understood, but the subjective psychedelic experience appears necessary for therapeutic effects, possibly serving as a turning point that elicits lasting behavioral change. Randomized, placebo-controlled trials are needed and some are underway. Even with compelling evidence, these substances may face challenges to integration into current treatment paradigms due to clinician concerns about addictive potential and philosophical objections from 12-step facilitation programs.
Psychiatric Annals February 1, 2020 Lynnette A. Averill, Christopher L. Averill, Chadi G. Abdallah 6 citations
Ketamine's discovery as a rapid antidepressant has transformed drug development and understanding of chronic stress pathology. This review covers the history of NMDA receptor modulators leading to ketamine's psychiatric use, its rapid antidepressant and antisuicidal effects, a model of synaptic loss and dysconnectivity underlying chronic stress pathology, clinically relevant biomarkers and mechanisms, and how ketamine may both reverse chronic stress pathology and serve as a research tool. The authors discuss outstanding questions and the ongoing debate between optimism and concern about ketamine's widespread use.
Psychiatric Annals September 1, 2022 Mitch Earleywine, Zachary Herrmann 5 citations
Serotonergic psychedelics such as psilocybin, LSD, and ayahuasca, when paired with supportive therapy, have reduced end-of-life anxiety in cancer patients, treatment-resistant depression, alcohol dependence, social anxiety in autistic adults, and nicotine dependence. MDMA-assisted therapy improves PTSD symptoms. Meta-analyses show promising effect sizes, but concerns remain about brief follow-ups, small samples, and poorly understood mechanisms. Generalization to the public is premature, and the proliferation of specialized clinics is not yet justified. Continued coordinated trials and judicious application are recommended, with realistic expectations that replication may yield smaller effects.
Psychiatric Annals December 1, 2023 Fernando Espi Forcen 3 citations
Spirituality among Hispanic and Latinx people takes many forms. While Catholicism has been dominant for centuries, Native American and African spiritual traditions have experienced a revival in recent decades. At the same time, Evangelical Christianity is rapidly growing in popularity across Latin America, reflecting the influence of the United States. To properly study these spiritual practices, researchers must understand the historical changes that shaped these religions and the context in which they became established in the region.
Psychiatric Annals March 1, 1994 David E Smith, Richard B Seymour 3 citations
There is growing concern over long-term perceptual disorder following hallucinogen use.
Psychiatric Annals March 1, 1994 Robert L. Dupont, Karl Verebey 1 citation
LSD, Ecstasy, and other hallucinogenic drugs like psilocybin and mescaline are frequently abused and widely available illicit substances, yet they are rarely detected in standard drug tests. This anomaly highlights a gap between their prevalence of use and the ability of routine toxicology screenings to identify them.
Psychiatric Annals June 1, 2024 Syed Iqbal, Ronak Patel, Zeshan Barlas et al.
Ketamine, an NMDA receptor antagonist, has antidepressant and antisuicidal effects shown over the past two decades and is effective for treatment-resistant depression. The FDA has approved intranasal (S)-ketamine with an oral antidepressant for this condition. However, the need for in-office administration and monitoring limits accessibility, and concerns about risks and abuse potential remain. Despite these drawbacks, its potential efficacy makes it a useful treatment for patients with treatment-resistant depression and suicidality.
Psychiatric Annals February 1, 2020 Hatice Guncu Kurt, Murat Altinay, Amit Anand
Patients unresponsive to two antidepressant trials are considered to have treatment-resistant depression (TRD). A review of open-label studies found that various pharmacological and brain stimulation treatments produce similar response rates of 30% to 70% and remission rates of 20% to 50%. In randomized placebo-controlled trials, response rates ranged from 15% to 60% and remission rates from 10% to 40%. Ketamine and electroconvulsive therapy achieve rates at the higher ends of these ranges, with the advantage of rapid action in acute settings. Direct comparative studies with large samples are needed to determine if one treatment offers greater benefit.
Psychiatric Annals September 1, 2022 Fernando Espí Forcén, Maren Nyer
Ketamine is the only prescribable psychedelic medicine in the United States and a promising treatment for depression. Most ketamine clinics currently administer ketamine without psychotherapy. This article reviews recent literature on combining ketamine with psychotherapy for psychiatric disorders, opening discussion on whether combined treatment offers benefits over ketamine alone.